LPL Financial LLC Has $693,000 Stock Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV)

LPL Financial LLC increased its position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 196,833 shares of the biopharmaceutical company’s stock after buying an additional 5,500 shares during the period. LPL Financial LLC owned 0.57% of Achieve Life Sciences worth $693,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC lifted its holdings in shares of Achieve Life Sciences by 74.8% in the 4th quarter. SG Americas Securities LLC now owns 19,886 shares of the biopharmaceutical company’s stock worth $70,000 after purchasing an additional 8,512 shares in the last quarter. Sigma Planning Corp acquired a new position in shares of Achieve Life Sciences during the fourth quarter valued at about $37,000. SBI Securities Co. Ltd. acquired a new stake in shares of Achieve Life Sciences in the 4th quarter worth about $49,000. Intech Investment Management LLC acquired a new stake in shares of Achieve Life Sciences in the 4th quarter worth about $58,000. Finally, State Street Corp lifted its position in Achieve Life Sciences by 6.8% in the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock valued at $2,045,000 after acquiring an additional 27,419 shares in the last quarter. 33.52% of the stock is owned by institutional investors.

Achieve Life Sciences Stock Performance

Shares of ACHV opened at $2.48 on Wednesday. The firm has a market capitalization of $86.02 million, a P/E ratio of -2.19 and a beta of 1.59. Achieve Life Sciences, Inc. has a 52 week low of $1.84 and a 52 week high of $5.59. The stock has a 50 day moving average price of $2.69 and a two-hundred day moving average price of $3.60. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.06). Equities analysts forecast that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current fiscal year.

Insider Activity at Achieve Life Sciences

In other news, CFO Mark K. Oki acquired 10,000 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was purchased at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the purchase, the chief financial officer now owns 10,000 shares in the company, valued at approximately $28,900. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.00% of the stock is owned by insiders.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.